Clinical Trial Update: A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating BI 770371 in combination with pembrolizumab, with or without cetuximab, versus pembrolizumab alone in head and neck squam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BI 770371
• ERBITUX (cetuximab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: RECRUITING